Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
5-FU + pembrolizumab is a combination regimen consisting of the fluoropyrimidine chemotherapy agent fluorouracil (5-FU) and the immune checkpoint inhibitor pembrolizumab. Fluorouracil is a small molecule that acts as a thymidylate synthase inhibitor, disrupting DNA and RNA synthesis to inhibit cancer cell proliferation. Pembrolizumab is a humanized IgG4 monoclonal antibody that targets the programmed death-1 (PD-1) receptor on T cells, preventing its interaction with PD-L1 and PD-L2 ligands, thereby restoring the anti-tumor immune response. This combination is being investigated in neoadjuvant settings, such as for locally advanced rectal cancer, often in conjunction with radiotherapy or as part of personalized treatment strategies guided by tumor organoid sensitivity testing.
- Brand names
- KeytrudaAdrucil
- Other names
- 5-fluorouracil + pembrolizumab5-FU + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + pembrolizumab.